1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 129,00 | 133,00 | 26.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Belite Bio: H.C. Wainwright bestätigt Kursziel von 200 Dollar nach Abschluss des Zulassungsantrags | 1 | Investing.com Deutsch | ||
| 16.06. | Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion | 3 | Investing.com | ||
| 13.06. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.06. | Belite Bio, Inc: Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 | 459 | GlobeNewswire (Europe) | SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting... ► Artikel lesen | |
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 01.06. | Full Transcript: Belite Bio Q1 2026 Earnings Call | 2 | Benzinga.com | ||
| 26.05. | Mizuho lowers Belite Bio stock price target to $215 on valuation | 2 | Investing.com | ||
| 22.05. | Benchmark reiterates Belite Bio stock rating on drug development progress | 5 | Investing.com | ||
| 21.05. | H.C. Wainwright reiterates Belite Bio stock rating on NDA progress | 2 | Investing.com | ||
| 21.05. | Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team | 2 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft EPS-Prognose für Q1 2026, Aktie gibt dennoch nach | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio Non-GAAP EPS of -$0.34 beats by $0.30 | 3 | Seeking Alpha | ||
| 20.05. | Belite Bio übertrifft Erwartungen im ersten Quartal - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 20.05. | Belite Bio, Inc: Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update | 429 | GlobeNewswire (Europe) | Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected... ► Artikel lesen | |
| 20.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.05. | Belite Bio receives Swiss orphan drug status for tinlarebant | 3 | Investing.com | ||
| 18.05. | Belite Bio, Inc: Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland | 269 | GlobeNewswire (Europe) | Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase... ► Artikel lesen | |
| 13.05. | Belite Bio, Inc: Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results | 4 | GlobeNewswire (USA) | ||
| 21.04. | Belite Bio begins rolling NDA submission for Stargardt treatment | 2 | Investing.com | ||
| 21.04. | Belite Bio startet schrittweises Zulassungsverfahren für Stargardt-Therapie | 1 | Investing.com Deutsch | ||
| 21.04. | Belite Bio, Inc: Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease | 525 | GlobeNewswire (Europe) | Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,85 | -0,13 % | BioNTech-Aktie: Ist das Unternehmen noch zu retten? | Die Geschichte von BioNTech ist eine der größten Erfolgsgeschichten der deutschen Wirtschaft. Aus einem Mainzer Forschungsunternehmen wurde innerhalb weniger Jahre ein globaler Pharmakonzern, dessen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,750 | -2,97 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 11,440 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Announces Asset Sale Agreements; Commences Chapter 11 Proceedings | INDIANAPOLIS (dpa-AFX) - Sangamo Therapeutics has entered into two separate asset sale agreements, one with Eli Lilly and Company (LLY) for Sangamos capsid delivery platform, zinc finger platform... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,300 | -0,30 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INFLARX | 1,687 | -0,24 % | InflaRx NV im Höhenflug: Was hinter dem Kursanstieg wirklich steckt - Was ich konkret unternommen habe! | ||
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| ABIVAX | 84,15 | +4,08 % | Biotech Hoffnung erhält Dämpfer: Abivax Aktie stürzt nach Höhenflug ab Krebs Signale belasten Investmentstory | Die Abivax Aktie hat nach ihrem starken Höhenflug einen herben Rückschlag erlitten. Auslöser sind neue Sicherheitsfragen rund um den Hoffnungsträger Obefazimod. Obwohl der Wirkstoff in klinischen Studien... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 0,931 | +1,42 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| GERON | 1,139 | 0,00 % | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights | Achieved $51.8 million in RYTELO- (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating... ► Artikel lesen | |
| BASILEA | 55,90 | -0,36 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 70,92 | +2,13 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) | REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 130,00 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.